Association Between Real-Time Continuous Glucose Monitor Use and Diabetes-Related Medical Costs for Patients with Type 2 Diabetes.
Diabetes Technol Ther
; 24(7): 520-524, 2022 07.
Article
de En
| MEDLINE
| ID: mdl-35230158
ABSTRACT
Little is known about the impact of real-time continuous glucose monitoring (rtCGM) on diabetes-related medical costs within the type 2 diabetes (T2D) population. A retrospective analysis of administrative claims data from the Optum Research Database was conducted. Changes in diabetes-related health care resource utilization costs were expressed as per-patient-per-month (PPPM) costs. A total of 571 T2D patients (90% insulin treated) met study inclusion criteria. Average PPPM for diabetes-related medical costs decreased by -$424 (95% confidence interval [CI] -$816 to -$31, P = 0.035) after initiating rtCGM. These reductions were driven, in part, by reductions in diabetes-related inpatient medical costs -$358 (95% CI -$706 to -$10, P = 0.044). Inpatient hospital admissions were reduced on average -0.006 PPPM (P = 0.057) and total hospital days were reduced an average of -0.042 PPPM (P = 0.139). These findings provide real-world evidence that rtCGM use was associated with diabetes-related health care resource utilization cost reductions in patients with T2D.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Diabète de type 2
Type d'étude:
Health_economic_evaluation
/
Observational_studies
/
Risk_factors_studies
Limites:
Humans
Langue:
En
Journal:
Diabetes Technol Ther
Sujet du journal:
ENDOCRINOLOGIA
/
TERAPEUTICA
Année:
2022
Type de document:
Article
Pays d'affiliation:
États-Unis d'Amérique